Czech/SlovakiaCzech RepublicSlovakia

National platform to boost industrial biotechnology


Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D, Innovation, and Policy) that monitor the current development stage of industrial biotechnology worked out at a two day roundtable that brought together Czech biotech experts with representatives from EuropaBio, SusChem, the EU-tech platform for sustainable chemistry, and the European Commission in Brno.

Enabling better tech transfer

“The Czech Republic had a great past in traditional biotechnology – in fermentation, continuous culture, or biotransformations. And it pioneered antibiotic production,” summarised Dr. Peter Sebo, biotechnologist at the Czech Academy of Sciences in Prague. “But currently, there are several bottlenecks that hamper the development of modern biotechnology.” Only four out of 42 modern biotech companies (Lonza, Baxter, Comtipor, ExBio) located in the Czech Republic are currently active in industrial biotech. Sebo estimates the industry in the Czech Republic as a whole employs about 2,000 staff and has turnover of roughly EUR200m per year, but added that there is limited R&D in advanced biotech, almost no biotech IP and thus no venture capital available. Nevertheless, he remained optimistic about the future. An Institute of Biotechnology was founded this January, while a biotech and biomed research centre called BIOCEV, which by 2012 will provide labs for 450 researchers and 150 students, is being built up in Prague. Last but not least, the government has established long term funding schemes for biotechnology. “Currently we have more funding than biotech people,” said Sebo.
On a national scale, the experts called for a specific funding program for white biotech that links national participants from industry and research, as well as for the launch of an awareness campaign for communicating the advantages of White Biotech to politicians and the public. They also re­commended improving technology transfer from research to industry, and educational programs to address the lack of managerial skills among researchers. Finally, they concluded that the construction of an open production plant would give Czech biotech companies the opportunity to test large-scale production without having to build costly production facilities on their own.
At the European level, they asked for a harmonisation of IP rights, additional funding for basic research projects, less bureaucracy, and the establishment of a European seed funding programme.
“The meeting has helped to better inform the Commission about industrial biotech, and map the possibility of further financial support tailored to the Czech specific situation,” said Michal Kostka, Deputy Director of the South Moravian Innovation Centre. The round table was the first in a series of meetings in which SusChem will be assessing White Biotech activities in eight Eastern EU member states.

Czech/SlovakiaCzech RepublicSlovakia


The Czech government has beefed up its investments in biotech with the help of EU structural funds. In February, the country’s Education Minister Josef Dobes gave the go-ahead for the Biocev centre in Vestec near Prague. Although...

Czech/SlovakiaCzech RepublicSlovakia


Brno – Czech Prime Minister Petr Necas has officially inaugurated the first of six European Technology Institutes slated to be launched in the Czech Republic with help from European FEDER funds. Although construction of the €200m...

Czech/SlovakiaCzech RepublicSlovakia


Prague – Czech drug developer VUAB Pharma a.s. has joined CzechBio. The company, which has its headquarters in Roztoky near Prague, became the 35th member of the Czech biotechnology industry association in September. VUAB...

Czech/SlovakiaCzech RepublicSlovakia


Praque – A team of researchers headed by Dr. Valdimir Kral, Director of Chemical Development at Sanofi-Aventis’ Czech research unit Zentiva Development sro, has presented a new targeted drug delivery system that couples combined...

Czech/SlovakiaCzech RepublicSlovakia


Brno – Plans for building a Central European Insitute of Technology (CEITEC) in Brno look set to take a big step closer to becoming reality. In mid-May, CEITEC representatives announced that EU financing for the EUR260m...

Czech/SlovakiaCzech RepublicSlovakia


Plzen – Czech antibody discovery and development specialist AbCheck s.r.o. has signed its first contract with a big pharma company. In October, the yearling Czech spin-off from German antibody drug developer Affimed GmbH...

Czech/SlovakiaCzech RepublicSlovakia


Prague – CzechInvest has called on Czech high-tech companies in the field of ICT, bio­technology, clean technology and micro­electronics to apply for the Czech Technology Accelerator programme. Under the third call, which was...

Czech/SlovakiaCzech RepublicSlovakia


Prague – Czech researchers from Charles University in Prague have discovered a molecular biomarker that helps to predict toxicity and a higher risk for adverse effects in children with juvenile arthritis that are treated with...

Czech/SlovakiaCzech RepublicSlovakia


Prague – Czech biotech company Lenti­Kats AS has begun worldwide commercialisation of a patented, cost-effective encapsulation technology for use in the food and bio­pharmaceuticals industry. The company has discovered a way to...

Czech/SlovakiaCzech RepublicSlovakia


Sofia – Bulgaria’s parliament has approved a law that will in effect ban any cultivation of GMO crops in the country. “There will be no field on the country’s territory where GMOs can be cultivated,” said Kostadin Yazov from the...

Displaying results 1 to 10 out of 70

1-10 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • NOVACYT (F)1.63 EUR17.27%
  • PLETHORA (UK)3.38 GBP12.67%


  • BAYER (D)84.42 EUR-5.72%
  • ALMIRALL (E)13.37 EUR-5.51%
  • MOLOGEN (D)3.20 EUR-5.04%


  • GALAPAGOS (B)51.25 EUR28.6%
  • NICOX (F)10.90 EUR26.2%
  • GENMAB (DK)1205.00 DKK24.2%


  • BIONOR PHARMA (N)0.68 NOK-26.9%
  • MOBERG PHARMA (S)38.70 SEK-26.3%
  • BIOCARTIS GROUP NV (B)8.00 EUR-24.2%


  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.90 SEK1906.9%
  • NICOX (F)10.90 EUR489.2%


  • BB BIOTECH (D)43.88 EUR-84.9%
  • EVOCUTIS (UK)0.05 GBP-79.2%

No liability assumed, Date: 23.05.2016


All Events


Berlin (GER)



Biomedica 2016